Abstract:Diffusion magnetic resonance imaging (dMRI) provides insight into white matter (WM) microstructural changes in Alzheimer’s disease and mild cognitive impairment (MCI). The Alzheimer’s Disease Neuroimaging Initiative’s (ADNI) has currently extended its ADNI3 imaging protocol to include dMRI from Siemens, Philips and General Electric (GE) scanners, resulting in seven vendor‐specific dMRI acquisition protocols (Table1). Here we present the updated ADNI3 preprocessing pipeline1 (Figure1) for diffusion tensor imaging (DTI) metrics made available via ADNI’s database, and evaluate their utility for detecting WM differences associated with clinical impairment. Raw dMRI downloaded from ADNI are first denoised using DiPy’s principal component analysis (PCA) denoising algorithms: local PCA for zero‐padded k‐space data (GE), or Marchenko‐Pastur PCA for data with the original acquisition matrix (Siemens/Philips). dMRI are then corrected for Gibbs ringing, eddy currents using FSL’s eddy_cuda with repol outlier estimation and slice‐to‐volume correction, intensity inhomogeneity with ANTS N4, and echo‐planar imaging distortions with a three‐channel non‐linear registration of the subject‐level preprocessed average B0 image to the subject’s skull‐stripped T1‐weighted MRI. Bias field correction is applied again to dMRI with FSL‐FAST. DTI fractional anisotropy (FA), axial, mean and radial diffusivity (AxD, MD, RD) are estimated with FSL’s dtifit, using weighted least squares. The JHU ICBM‐DTI‐81 atlas FA is warped to subject‐level FA maps using ANTS, and the transformations are applied to atlas labels. Subject‐level mean and robust mean (using M‐estimator from R’s ‘WRS2’ package) of DTI metrics within 73 WM regions of interest (ROIs; Table2) are extracted. Here, we fit linear mixed effects models of diagnosis (N=733) and clinical dementia rating (CDR‐sob; N=682; Table3) in 28 of the 73 available ROIs, covarying for age, sex, age*sex, and including nested protocol|site variables as random effects; multiple comparisons were corrected for using false discovery rate (q=0.05). Lower anisotropy and greater diffusivity were associated with greater impairment, particularly in the hippocampal cingulum (Figure2). Results from mean and robust mean metrics were comparable. Overall, our results follow previous work2,3 using publicly available ADNI dMRI. Subject‐level ADNI3 dMRI measures, sensitive to clinical indices of impairment as presented here, are available at https://ida.loni.usc.edu/. References: [1 ]Thomopoulos (2021), https://doi.org/10.1117/12.2606337; [2] Nir (2013), https://doi.org/10.1016/j.nicl.2013.07.006; [3] Zavaliangos‐Petropulu (2019), https://doi.org/10.3389/fninf.2019.00002.

Overview of ADNI MRI

The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative

The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials

The Alzheimer's Disease Neuroimaging Initiative Positron Emission Tomography Core

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease

Morphometry of medial temporal lobe subregions using high-resolution T2-weighted MRI in ADNI3: Why, how, and what's next?

Arterial spin labeling perfusion MRI in the Alzheimer's Disease Neuroimaging Initiative: Past, present, and future

Effects of Dementia and MCI on Diffusion Tensor Metrics Using the Updated ADNI3 DTI Preprocessing Pipeline

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

ADNI Biomarker Core: A review of progress since 2004 and future challenges

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives

Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)

Surface-based parcellation and vertex-wise analysis of ultra high-resolution ex vivo 7 tesla MRI in Alzheimer's disease and related dementias

Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

Implementing ABCD studyⓇ MRI sequences for multi-site cohort studies: Practical guide to necessary steps, preprocessing methods, and challenges

IC-03-06: Six Month MRI Gray Matter Declines in Alzheimer's Dementia Evaluated by Voxel-Based Morphometry with Multivariate Network Analysis: Preliminary Findings from the ADNI Study

ANSH: Multimodal Neuroimaging Database Including MR Spectroscopic Data From Each Continent to Advance Alzheimer's Disease Research

Contributions of the ADNI Biostatistics Core

O1-02-06: Twelve-month Cerebral Metabolic Declines in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI)